Schering-Plough's boceprevir continues to show promise in hepatitis C
30 April 2009
John Davis
Please Login to read the full article.
30 April 2009
John Davis
John.davis@informa.com
Schering-Plough's investigational hepatitis C therapy boceprevir has continued to show promise in a Phase II trial, with a doubling of the sustained virologic response (SVR) compared with control therapy.
Preliminary results from the SPRINT-1 trial involving boceprevir, an oral protease inhibitor...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Merck's boceprevir cuts treatment times for hepatitis C
- Payers and patient compliance will determine winners as Incivek and Victrelis hit HCV
- Achillion raising $56.6 million to advance hepatitis C candidates
- Hep C contenders Merck, Roche form pact to market Victrelis, pursue R&D
FEATURES
Other Informa Features
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
